Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.
|Title||Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.|
|Publication Type||Journal Article|
|Year of Publication||2003|
|Authors||Arnold, EL, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E|
|Journal||Journal of the American Academy of Child and Adolescent Psychiatry|
|Date Published||2003 Dec|
|Keywords||Adolescent, Adult, Affect, Aggression, Autistic Disorder, Child, Clinical Trials as Topic, Dopamine Antagonists, Double-Blind Method, Endpoint Determination, Female, Humans, Male, Observer Variation, Parent-Child Relations, Placebos, Research Design, Risperidone, Severity of Illness Index, Stereotyped Behavior, Treatment Outcome|
A consumer-oriented efficacy assessment in clinical trials should measure changes in chief complaint and consumer request (symptoms of most concern to patient/caregiver), which may be diluted in change scores of multisymptom scales.
|Alternate Journal||J Am Acad Child Adolesc Psychiatry|